Physiology and blood chemistry changes of the dying phase
What happens in the body during the last days of life: falling intake and circulation, prerenal kidney failure, rising urea, sodium, potassium and calcium, lactate and bilirubin, the mechanisms behind Cheyne-Stokes breathing, mottling, noisy breathing and reduced consciousness, why opioid metabolites accumulate, and why routine blood tests should usually stop.
Tier 1Medical sciences concept
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- Dying is a final common pathway: whatever the disease, the last days bring falling intake, falling cardiac output, prerenal kidney failure, reduced consciousness and changed breathing.
- Blood chemistry follows predictably: urea and creatinine rise (urea more), sodium rises with free water loss, potassium rises with falling GFR and acidosis, lactate rises with hypoperfusion, and bilirubin, CRP and white cell count often climb. Albumin falls.
- These changes contribute to drowsiness and delirium but are rarely worth correcting. Routine blood tests and observations should stop once dying is recognised.
Loading the rest of the note…
Finished reading?
Sources
- Therapeutic Guidelines: Palliative Care (eTG complete), version 5AU/NZTherapeutic Guidelines Limited, 2024 (version 5, December 2024)
- National Consensus Statement: Essential elements for safe and high-quality end-of-life care (2nd edition)AU/NZAustralian Commission on Safety and Quality in Health Care, 2023
- NICE guideline NG31: Care of dying adults in the last days of lifeNational Institute for Health and Care Excellence, 2015 (current at November 2026)
- Hui D et al. Clinical signs of impending death in cancer patients. Oncologist 2014;19:681-687The Oncologist, 2014
- Hui D et al. Bedside clinical signs associated with impending death in patients with advanced cancer. Cancer 2015;121:960-967Cancer, 2015
- Bruera E et al. Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial. J Clin Oncol 2013;31:111-118Journal of Clinical Oncology, 2013
- Oxford Textbook of Palliative Medicine (6th ed.)Oxford University Press (Cherny, Fallon, Kaasa, Portenoy and Currow, eds), 2021
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback